InnoCare

Focus: InnoCare is a Beijing-based oncology-focused biotech company founded in 2024, now publicly listed with a diversified pipeline spanning cancer, immunology, and dermatology indications.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About InnoCare

AI assessmentNot Hiring

No open roles listed right now. Follow InnoCare to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

[14C]ICP-022

Healthy Volunteers

N/A

Clinical Trials (1)

NCT04441450ADME Study of [14C]ICP-022 in Healthy Males

N/A

Help build intelligence for InnoCare

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

30 active pipeline programs across multiple therapeutic areas with 9 Phase 3 candidates, offering exposure to late-stage drug development and regulatory strategy
Public company status provides equity upside and institutional visibility rare for a 2024-founded biotech
Diverse modality platform (BTK inhibitors, JAK inhibitors, checkpoint inhibitors) suggests strong technical depth across oncology and immunology

Watch Out For

Zero active job openings and missing employment count raise immediate red flags about current hiring activity and company sizing
Sparse financial data (no revenue, R&D spend, or cash position disclosed) prevents assessment of runway, burn rate, and long-term stability
Early-stage company with heavy Phase 1-2 exposure (15 of 20 programs) means 5+ years to meaningful commercial validation

Generated by Claude from InnoCare's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Orelabrutinib

Neuromyelitis Optica Spectrum Disorder

N/A

Clinical Trials (1)

NCT05284175A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder

N/A

ICP-189

Patients With Advanced Solid Tumors

PHASE_1

Clinical Trials (1)

NCT05370755A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Phase 1

CM369

Advanced Solid Tumors and Hematologic Malignancies

PHASE_1

Clinical Trials (1)

NCT05690581Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies

Phase 1

ICP-022

Systemic Lupus Erythematosus

PHASE_1

Clinical Trials (1)

NCT03189017A Phase I Study of ICP-022 in Healthy Subjects

Phase 1

Orelabrutinib Tablets

Hepatic Impairment

PHASE_1

Clinical Trials (1)

NCT05684653Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject

Phase 1

ICP-248

Acute Myelogenous Leukemia

PHASE_1

Clinical Trials (1)

NCT06656494ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Phase 1

Orelabrutinib and placebo

Healthy Subject

PHASE_1

Clinical Trials (1)

NCT05660720Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

Phase 1

ICP-248

Hematological Malignancies

PHASE_1

Clinical Trials (1)

NCT05728658The Study of ICP-248 in Patients With Mature B-cell Malignancies

Phase 1

ICP-033 tablet

Patients With Advanced Solid Tumors

PHASE_1

Clinical Trials (1)

NCT05367232A Study of ICP-033 in Patients With Advanced Solid Tumors

Phase 1

ICP-723

Advanced Solid Tumors

PHASE_1

Clinical Trials (1)

NCT05537987Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors

Phase 1

ICP-488

Psoriasis

PHASE_1

Clinical Trials (1)

NCT05451199A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis

Phase 1

ICP-248

Mature B-cell Malignancies

PHASE_1

Clinical Trials (1)

NCT06351527Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

Phase 1

ICP-332 Tablets

Healthy Subjects

PHASE_1

Clinical Trials (1)

NCT06530966Phase I Study of ICP-332 in Healthy Subjects

Phase 1

ICP-B794

Advanced Solid Tumors

PHASE_1

Clinical Trials (1)

NCT07136558Evaluation of ICP-B794 in Patients With Advanced Solid Tumors